A Randomised, Double-blind, Placebo-controlled, Single Ascending Dose, Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PG110 (Anti-NGF Monoclonal Antibody) in Patients With Pain Attributed to Osteoarthritis of the Knee.
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2011
At a glance
- Drugs ABT 110 (Primary)
- Indications Musculoskeletal pain; Osteoarthritis
- Focus Adverse reactions
- 06 Jun 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.
- 06 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jan 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.